PCN40 COST ANALYSIS OF MANAGING ADVERSE EVENTS IN THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN PORTUGAL- A COMPARISON OF BEVACIZUMAB IN COMBINATION WITH INTERFERON ALFA-2A AND SUNITINIB
Abstract
Authors
CI Silva I Monteiro B Schwander